Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.34 |
| ▸ | LOX | P28300 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2714396 | 0.98 | L3MBTL1 (0.39) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| SCHEMBL3890599 | 0.86 | L3MBTL1 (0.53) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| SCHEMBL30939139 | 0.86 | L3MBTL1 (0.53) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| Hydrochloric Acid SCHEMBL2713855 | 0.85 | L3MBTL1 (0.51) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| Hydrochloric Acid SCHEMBL5012085 | 0.85 | L3MBTL1 (0.51) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| SCHEMBL2714106 | 0.83 | L3MBTL1 (0.43) | L3MBTL1POLBMAPK1SCN9AMAPT | |
| SCHEMBL1461744 | 0.83 | L3MBTL1 (0.36) | L3MBTL1LOXL2LOXMAPTDGAT1 | |
| SCHEMBL18266635 | 0.83 | L3MBTL1 (0.40) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| SCHEMBL4550753 | 0.83 | L3MBTL1 (0.40) | L3MBTL1POLBMAPK1SCN9ALOXL2 | |
| Hydrochloric Acid SCHEMBL2714047 | 0.82 | L3MBTL1 (0.39) | L3MBTL1POLBMAPK1SCN9ALOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | L3MBTL1 2429/4885POLB 4126/4885MAPK1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.